arginine aspartate: RN given refers to (L)-isomer of aspartic acid with L-arginine (1:1) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11500504 |
| SCHEMBL ID | 150229 |
| MeSH ID | M0083613 |
| Synonym |
|---|
| einecs 231-656-8 |
| arginine aspartate |
| l-aspartic acid, compound with l-arginine (1:1) |
| 7675-83-4 |
| sargenor (tn) |
| D07574 |
| (2s)-2-aminobutanedioic acid; (2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid |
| (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid; (2s)-2-azanylbutanedioic acid |
| A838816 |
| l-arginine l-aspartate |
| c10h21n5o6 |
| AKOS015999535 |
| pargine |
| targifor |
| l-arginine aspartate |
| unii-lzb1g2i725 |
| lzb1g2i725 , |
| arginine, l-, l-aspartate (1:1) |
| arginine aspartate [mart.] |
| aspartic acid compound with l-arginine [mi] |
| arginine aspartate [ep monograph] |
| (2s)-2-amino-5-guanidinopentanoic acid (2s)-2-aminobutanedioate |
| arginine aspartate [inci] |
| arginine aspartate [who-dd] |
| sargenor |
| arginine l-aspartate |
| arginine l-aspartate [who-dd] |
| SCHEMBL150229 |
| Q-201278 |
| l-arg l-asp |
| mfcd00058334 |
| arginine aspartate (l-arginine l-aspartate) |
| l-arginine-l-aspartate |
| F11039 |
| (s)-2-amino-5-guanidinopentanoic acid compound with (s)-2-aminosuccinic acid (1:1) |
| AS-12827 |
| AMY25319 |
| l-argininel-aspartate |
| (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid |
| Q27283267 |
| DTXSID70884415 |
| l-arginine l-aspartate 100 microg/ml in water |
| CS-0158451 |
Oral arginine aspartate treatment effects (acute administration: 1 g 30 minutes after load, chronic administration: 0.33 g a day during 9 months) are researched on rabbit acute alcoholizing load (1 ml alcohol 40 degrees/100 g) and alcohol chronic intoxication. Treatment with arginin showed complete clinical and biochemical recovery.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Oral arginine aspartate treatment effects (acute administration: 1 g 30 minutes after load, chronic administration: 0.33 g a day during 9 months) are researched on rabbit acute alcoholizing load (1 ml alcohol 40 degrees/100 g) and alcohol chronic intoxication (0,5 ml alcohol 40 degrees/100 g a day during 9 months). " | ( [Arginine aspartate effects on rabbit acute and chronic alcoholization (author's transl)]. Elsair, J; Hattab, F; Poey, J; Reggabi, M; Spinner, C; Zidane, C, 1978) | 1.68 |
| "Treatment with arginine aspartate showed complete clinical and biochemical recovery." | ( Pyruvate dehydrogenase deficiency: identification of a novel mutation in the PDHA1 gene which responds to amino acid supplementation. Eusébio, F; Gaspar, A; João Silva, M; Pinheiro, A; Rivera, I; Tavares de Almeida, I, 2009) | 0.69 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The chronic intake of arginine asparate during four weeks by male endurance athletes showed independent of dosage no influence on performance, selected metabolic or endocrine parameters." | ( Influence of chronic supplementation of arginine aspartate in endurance athletes on performance and substrate metabolism - a randomized, double-blind, placebo-controlled study. Abel, T; Eser, P; Knecht, H; Knechtle, B; Perret, C; von Arx, P, 2005) | 0.6 |
| " This pilot phase II study showed that the on-demand oral administration at a high dosage of l-arginine aspartate-adenosine monophosphate combination may be effective in patients with mild-to-moderate ED, is very well tolerated and could be tested as a safe first-line therapy in a larger size phase III study." | ( A randomized, double-blind, crossover, placebo-controlled comparative clinical trial of arginine aspartate plus adenosine monophosphate for the intermittent treatment of male erectile dysfunction. Botto, H; Cour, F; Hupertan, V; Lebret, T; Neuzillet, Y, 2013) | 0.83 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (34.62) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 5 (19.23) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.10) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 12 (38.71%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (3.23%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (58.06%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||